Purpose: The aim of this study is to reduce treatment planning time by predicting the intensity‐modulated radiotherapy 3D dose distribution using deep learning for brain cancer patients. “For this purpose, two different approaches in dose prediction, i.e., first only planning target volume (PTV) and second PTV with organs at risk (OARs) as input of the U‐net model, are employed and their results are compared.”Methods and Materials: The data of 99 patients with glioma tumors referred for IMRT treatment were used so that the images of 90 patients were regarded as training datasets and the others were for the test. All patients were manually planned and treated with sixth‐field IMRT; the photon energy was 6MV. The treatment plans were done with the Collapsed Cone Convolution algorithm to deliver 60 Gy in 30 fractions.Results: The obtained accuracy and similarity for the proposed methods in dose prediction when compared to the clinical dose distributions on test patients according to MSE, dice metric and SSIM for the Only‐PTV and PTV‐OARs methods are on average (0.05, 0.851, 0.83) and (0.056, 0.842, 0.82) respectively. Also, dose prediction is done in an extremely short time.Conclusion: The same results of the two proposed methods prove that the presence of OARs in addition to PTV does not provide new knowledge to the network and only by defining the PTV and its location in the imaging slices, does the dose distribution become predictable. Therefore, the Only‐PTV method by eliminating the process of introducing OARs can reduce the overall designing time of treatment by IMRT in patients with glioma tumors.
28 October 2025 in Indian Journal of Surgical Oncology
Background: The present research was aimed to compare the toxicity and effectiveness of conventional fractionated radiotherapy versus hypo-fractionated radiotherapy in breast cancer utilizing a radiobiological model. Materials and methods: Thirty-five left-sided breast cancer patients without involvement of the supraclavicular and axillary lymph nodes (with the nodal stage of N0) that had been treated with conventional or hypo-fractionated were incorporated in this study. A radiobiological model was performed to foretell normal tissue complication probability (NTCP) and tumor control probability (TCP). Results: The data represented that TCP values for conventional and hypo-fractionated regimens were 99.16 ± 0.09 and 95.96 ± 0.48, respectively (p = 0.00). Moreover, the NTCP values of the lung for conventional and hypo-fractionated treatment were 0.024 versus 0.13 (p = 0.035), respectively. Also, NTCP values of the heart were equal to zero for both regimens. Conclusion: In summary, hypo-fractionated regimens had comparable efficacy to conventional fraction radiation therapy in the case of dosimetry parameters for patients who had left breast cancer. But, utilizing the radiobiological model, conventional fractionated regimens presented better results compared to hypo-fractionated regimens. Background: The present research was aimed to compare the toxicity and effectiveness of conventional fractionated radiotherapy versus hypo-fractionated radiotherapy in breast cancer utilizing a radiobiological model. Materials and methods: Thirty-five left-sided breast cancer patients without involvement of the supraclavicular and axillary lymph nodes (with the nodal stage of N0) that had been treated with conventional or hypo-fractionated were incorporated in this study. A radiobiological model was performed to foretell normal tissue complication probability (NTCP) and tumor control probability (TCP). Results: The data represented that TCP values for conventional and hypo-fractionated regimens were 99.16 ± 0.09 and 95.96 ± 0.48, respectively (p = 0.00). Moreover, the NTCP values of the lung for conventional and hypo-fractionated treatment were 0.024 versus 0.13 (p = 0.035), respectively. Also, NTCP values of the heart were equal to zero for both regimens. Conclusion: In summary, hypo-fractionated regimens had comparable efficacy to conventional fraction radiation therapy in the case of dosimetry parameters for patients who had left breast cancer. But, utilizing the radiobiological model, conventional fractionated regimens presented better results compared to hypo-fractionated regimens.
Background: Multiple sclerosis (MS) is a chronic neuroinflammatory condition characterised by demyelination and axonal damage in the central nervous system. Diffusion tensor imaging (DTI) enables non-invasive investigation of microstructural white matter alterations, while serum neurofilament light chain (NFL) holds promise as a fluid biomarker of axonal injury. Objectives: To use DTI and serum NFL measurements to evaluate white matter pathology in patients with MS and explore the relationship between in vivo imaging and biochemical indicators of axonal damage. Methods: 41 patients with relapse-remitting MS and 41 age-matched healthy controls underwent brain MRI including DTI acquisition. Serum samples were analysed for NFL concentrations using ELISA. Region of interest analysis was conducted to derive DTI metrics including fractional anisotropy, mean diffusivity, axial diffusivity and radial diffusivity. Correlational analyses were used to explore the associations between the imaging and biochemical indices. Results: Patients exhibited significantly elevated serum NFL levels and altered DTI metrics compared with controls, indicative of axonal/myelin pathology. DTI parameters were positively correlated with serum NFL concentration (p value<0.0001). Visual analogue scale scores demonstrated a significant positive relationship between DTI metrics and NFL, validating their potential as radiological and fluid-based markers of symptom severity. Conclusions: Combined DTI and serum NFL measurements may enhance the evaluation of axonal injury in MS by providing complementary in vivo and biochemical perspectives. The corresponding changes observed between the modalities support their utility as non-invasive biomarkers reflecting pathophysiological processes and clinical status in MS. Larger validation cohorts are needed to determine the clinical applicability.
Background/Objectives: We conducted a comprehensive investigation to explore the pathological expression of the CXCR4 receptor in lymphoproliferative disorders (LPDs) using [68Ga]Ga-Pentixafor PET/CT or PET/MRI technology. The PICO question was as follows: What is the diagnostic role (outcome) of [68Ga]Ga-Pentixafor PET (intervention) in patients with LPDs (problem/population)? Methods: The study was written based on the reporting items for systematic reviews and meta-analyses (PRISMA) 2020 guidelines, and it was registered on the prospective register of systematic reviews (PROSPERO) website (CRD42024506866). A comprehensive computer literature search of Scopus, MEDLINE, Scholar, and Embase databases was conducted, including articles indexed up to February 2024. To the methodological evaluation of the studies used the quality assessment of diagnosis accuracy studies-2 (QUADAS-2) tool. Results: Of the 8380 records discovered, 23 were suitable for systematic review. Fifteen studies (on 571 LPD patients) focused on diagnosis and staging, and eight trials (194 LPD patients) assessed treatment response. Conclusions: The main conclusions that can be inferred from the published studies are as follows: (a) [68Ga]Ga-Pentixafor PET may have excellent diagnostic performance in the study of several LPDs; (b) [68Ga]Ga-Pentixafor PET may be superior to [18F]FDG or complementary in some LPDs variants and settings; (c) multiple myeloma seems to have a high uptake of [68Ga]Ga-Pentixafor. Overall, this technique is probably suitable for imaging, staging, and follow-up on patients with LPD. Due to limited data, further studies are warranted to confirm the promising role of [68Ga]Ga-Pantixafor in this context.